Description
BAY-1082439 is an inhibitor of PI3K. It is selective for the PI3Kα/β/δ isoforms. In vivo, BAY-1082439 has shown efficacy in inhibiting PTEN-null prostate cancer growth.
Product Unit Size | Cost | Quantity | Stock |
---|
BAY-1082439 is an inhibitor of PI3K. It is selective for the PI3Kα/β/δ isoforms. In vivo, BAY-1082439 has shown efficacy in inhibiting PTEN-null prostate cancer growth.
Cas No. | 1375469-38-7 |
---|---|
Purity | ≥98% |
Formula | C25H30N6O5 |
Formula Wt. | 494.55 |
IUPAC Name | N-{8-[(2R)-2-Hydroxy-3-(4-morpholinyl)propoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}-2-methylnicotinamide |
Synonym | BAY 1082439, BAY1082439, BAY10-82439, BAY 10-82439, BAY-10-82439 |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Zou Y., Qi Z., et al. Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439. Mol Cancer Ther. 17(10):2091-99 (2018). PMID: 30045927.
α1-adrenergic antagonist.
Prodrug
Melanoma-associated antigen.
Staurosporine analog; PKC inhibitor, TrkA/B ant...
Cell membrane permeability modulator, topoisome...
Mycotoxin produced by species of Aspergillus; D...
GHB agonist, D2/3 antagonist.
Triterpene saponin found in species of Panax.
Chloramphenicol derivative; protein translation...
Heterocyclic light-emitting compound, natural l...
Epoxomicin analog; proteasome inhibitor.
COVID-19 research
Endogenous quaternary ammonium, required for fa...
First generation fluoroquinolone antibiotic.
Nucleoside (adenosine) analog; P2Y12 antagonist...
STING antagonist
Dihydropyridine; L-type and T-type Ca2+ channel...
Hydrophobic β-lactam; penicillin binding prote...
Cysteine protease inhibitor.
Alters intracellular glutathione levels.